Search results for "choline"

showing 10 items of 1138 documents

Release of [3H]acetylcholine from a modified rat phrenic nerve-hemidiaphragm preparation

1986

Two different preparations of the rat phrenic nerve-hemidiaphragm (whole nerve-muscle preparation, end-plate preparation) were used for studying synthesis and release of radioactive acetylcholine in the absence and presence of cholinesterase inhibitors. When the whole nerve-muscle preparation (110-180 mg) was incubated with [3H]choline, only small amounts of radioactive acetylcholine were synthesized within the tissue. Electrical nerve stimulation of the whole nerve-muscle preparation produced no increase in tritium outflow. Incubation of the end-plate preparation (16-29 mg) which was obtained after removal of most of the muscle mass led to the formation of large amounts of [3H]acetylcholin…

MaleDiaphragmNeuromuscular JunctionStimulationIn Vitro TechniquesNeuromuscular junctionCholinechemistry.chemical_compoundmedicineAnimalsCholinePhrenic nerveCholinesterasePharmacologyNeurotransmitter AgentsbiologyRats Inbred StrainsHemicholinium 3General MedicineAcetylcholineMuscle DenervationRatsPhrenic Nervemedicine.anatomical_structurechemistryAnesthesiaTetrodotoxinbiology.proteinBiophysicsLiberationAcetylcholinemedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

alpha-Bungarotoxin, kappa-bungarotoxin, alpha-cobratoxin and erabutoxin-b do not affect [3H]acetylcholine release from the rat isolated left hemidiap…

1995

Endplate preparations of the rat left hemidiaphragm were incubated with [3H]choline to label neuronal transmitter stores. Nerve evoked release of newly-synthesized [3H]acetylcholine was measured in the absence of cholinesterase inhibitors to investigate whether snake venom neurotoxins by blocking presynaptic nicotinic autoreceptors affect evoked transmitter release. Contractions of the indirectly stimulated hemidiaphragm were recorded to characterize the blocking effect of alpha-neurotoxins at the post-synaptic nicotinic receptors. Neither the long chain neurotoxins alpha-cobratoxin (1 microgram ml-1) and alpha-bungarotoxin (5 microgram ml-1) nor the short chain neurotoxin erabutoxin-b (0.1…

MaleDiaphragmNeurotoxinsPharmacologyReceptors NicotinicTritiumSynaptic TransmissionPostsynaptic potentialmedicineAnimalsCobra Neurotoxin ProteinsChromatography High Pressure LiquidCholinesterasePharmacologyErabutoxinsbiologyChemistryMuscle SmoothGeneral MedicineBungarotoxinmusculoskeletal systemBungarotoxinsAcetylcholineRatsPhrenic NerveNicotinic agonistSnake venomIsotope Labelingbiology.proteinAutoreceptorFemaleCobratoxinNeuroscienceAcetylcholinemedicine.drugMuscle ContractionSnake VenomsNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

Effects of scopolamine on dopamine neurons in the substantia nigra : role of the pedunculopontine tegmental nucleus

2009

Previous neurochemical and behavioral studies suggest that muscarinic receptor antagonism has an excitatory effect on the nigrostriatal dopamine (DA) system. Using in vivo extracellular single unit recording, this study examined whether blockade of the muscarinic receptor by scopolamine alters the firing properties of DA neurons in the substantia nigra (SN). Scopolamine was administered either systemically or locally to DA neurons using microiontophoresis. Surprisingly, scopolamine did not cause any significant change in either the firing rate or pattern of the spontaneously active DA neurons. However, systemic injection of scopolamine significantly increased the number of active DA neurons…

MaleDopamineParkinson's diseaseScopolamineAction PotentialsSubstantia nigraMuscarinic AntagonistsStriatumelectrophysiology microiontophoresisSettore BIO/09 - FisiologiaRats Sprague-DawleyCellular and Molecular NeuroscienceDopamineBasal gangliaMuscarinic acetylcholine receptorPedunculopontine Tegmental NucleusmedicineSubstantia nigraAnimalsPedunculopontine Tegmental NucleusNeuronsAnalysis of VarianceDose-Response Relationship DrugChemistryDrug Administration RoutesIontophoresisAcetylcholineRatsSubstantia Nigranervous systemAutoreceptorBasal gangliaNeuroscienceAcetylcholinemedicine.drug
researchProduct

Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive blad…

2004

OBJECTIVE To assess the pharmacokinetics of a controlled-release formulation of oxybutynin (OROS®-O, ALZA Corp., Mountain View, CA) at different dosages, compared with immediate-release oxybutynin (IR-O), and to determine the pharmacodynamic properties in the severity-dependent reduction of urge urinary incontinence (UUI). PATIENTS AND METHODS In all, 105 patients were enrolled in this multicentre, randomized, double-blind study. Individual dose titration was used to assess the minimum effective, maximum tolerated or maximum allowed dose of either OROS-O or IR-O. Blood samples were collected during maintenance therapy with frequent sampling to analyse for R-oxybutynin and R-desethyloxybutyn…

MaleDoseUrologyUrinary incontinenceDouble-Blind MethodPharmacokineticsMaintenance therapymedicineHumansDosingOxybutyninDose-Response Relationship Drugbusiness.industryMiddle Agedmedicine.diseaseUrinary IncontinenceOveractive bladderDelayed-Action PreparationsAnesthesiaPharmacodynamicsMandelic AcidsFemaleCholinesterase Inhibitorsmedicine.symptombusinessmedicine.drugBJU International
researchProduct

Muscarinic Properties of Compounds Related to Arecaidine Propargyl Ester

2011

A series of new analogues of the arecaidine propargyl ester (CAS 35516-99-5, APE, 1a) with alcohols consisting of 4 or 5 carbon atoms were investigated at muscarinic receptor subtypes. The muscarinic activity of the quaternary and tertiary salts of the APE-related compounds were assayed on the isolated guinea-pig ileum (M 3 receptor subtype) and guinea-pig left atria (M 2 receptor subtype) as well as on rabbit isolated vas deferens (M 1 receptor subtype). The structural variations made in the APE molecule, replacing the triple bond in the ester side chain with structures such as double bond, an allene moiety, a single bond, a cyclopropyl group or two triple bonds should alter the selectivit…

MaleDouble bondStereochemistryArecolineGuinea PigsCholinergic AgentsIn Vitro Techniqueschemistry.chemical_compoundVas DeferensIleumDrug DiscoveryMuscarinic acetylcholine receptorAnimalsMoietySingle bondReceptorReceptor Muscarinic M3chemistry.chemical_classificationReceptor Muscarinic M2Receptor Muscarinic M1HeartMuscle SmoothArecaidineTriple bondMyocardial ContractionReceptors MuscarinicchemistryPropargylFemaleRabbitsMuscle ContractionArzneimittelforschung
researchProduct

Phospholipid breakdown and choline release under hypoxic conditions: inhibition by bilobalide, a constituent of Ginkgo biloba

1997

A marked increase of choline release from rat hippocampal slices was observed when the slices were superfused with oxygen-free buffer, indicating hypoxia-induced hydrolysis of choline-containing phospholipids. This increase of choline release was suppressed by bilobalide, an ingredient of Ginkgo biloba, but not by a mixture of ginkgolides. The EC50 value for bilobalide was 0.38 microM. In ex vivo experiments, bilobalide also inhibited hypoxia-induced choline release when given p.o. in doses of 2-20 mg/kg 1 h prior to slice preparation. The half-maximum effect was observed with 6 mg/kg bilobalide. A similar effect was noted after p.o. administration of 200 mg/kg EGb 761, a ginkgo extract con…

MaleDrug Evaluation PreclinicalCyclopentanesPharmacologyHippocampusCholinechemistry.chemical_compoundSlice preparationBilobalideAnimalsCholineRats WistarGinkgolidesFuransHypoxia BrainMolecular BiologyPhospholipidsEC50biologyPlant ExtractsGinkgo bilobaGeneral NeuroscienceGinkgobiology.organism_classificationRatsPlant LeavesGinkgolidesLogistic ModelschemistryBiochemistryNeurology (clinical)DiterpenesEx vivoDevelopmental BiologyBrain Research
researchProduct

Therapeutic Drug Monitoring for Patients With Alzheimer Dementia to Improve Treatment With Donepezil

2015

BACKGROUND Aiming to verify that therapeutic drug monitoring has the potential to optimize treatment with acetylcholine esterase inhibitors of patients with Alzheimer dementia, this study investigated whether serum concentrations of donepezil are associated with clinical improvement. METHODS Clinical improvement was measured using the clinical global impression (CGI) scale, and donepezil concentrations were measured in serum by a high-performance liquid chromatographic method with spectrophotometric detection. RESULTS In total, 206 serum samples from 106 patients (49.5% female) were retrospectively available for analysis. Patients included were treated under everyday conditions. Their mean …

MaleDrugmedicine.medical_specialtymedia_common.quotation_subjectGastroenterologyPiperidinesAlzheimer DiseaseInternal medicinemental disordersmedicineHumansDonepezilPharmacology (medical)DonepezilAgedRetrospective Studiesmedia_commonPharmacologyDose-Response Relationship DrugReceiver operating characteristicmedicine.diagnostic_testbusiness.industryRetrospective cohort studyAlzheimer dementiaDose–response relationshipTreatment OutcomeTherapeutic drug monitoringIndansClinical Global ImpressionFemaleCholinesterase InhibitorsDrug Monitoringbusinessmedicine.drugTherapeutic Drug Monitoring
researchProduct

Pattern of occult nodal relapse diagnosed with 18F-fluoro-choline PET/CT in prostate cancer patients with biochemical failure after prostate-only rad…

2014

Abstract Introduction The purpose of this study was to describe the pattern of nodal relapse with 18 F-fluoro-choline (FCH) Positron Emission Tomography/Computerized Tomography (PET/CT) in prostate cancer patients after radiotherapy. Materials and methods Eighty-three patients had a FCH PET/CT at time of biochemical failure. Of 65 patients with positive findings, 33 had positive nodes. This analysis included 31 patients who had undergone prior prostate-only radiotherapy with or without a prior radical prostatectomy. Each FCH positive node was assigned to a lymph node station with respect to the CTV defined by the RTOG guidelines (CTV RTOG ). 3D mapping was performed after each node was manu…

MaleFluorine Radioisotopesmedicine.medical_treatment[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineMultimodal Imaging[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicineCholineProstate cancerProstatemedicineHumansRadiology Nuclear Medicine and imagingLymph nodeComputingMilieux_MISCELLANEOUSSalvage TherapyPET-CTmedicine.diagnostic_testProstatectomybusiness.industryProstatic NeoplasmsHematologyProstate-Specific Antigenmedicine.diseaseOccult3. Good healthRadiation therapymedicine.anatomical_structureOncologyPositron emission tomographyLymphatic MetastasisPositron-Emission TomographyKallikreinsLymph NodesNeoplasm Recurrence LocalRadiopharmaceuticalsNuclear medicinebusinessTomography X-Ray Computed
researchProduct

Phospholipase D in heart: basal activity and stimulation by phorbol esters and aluminum fluoride

1992

Evidence for a general role of phospholipase D in signal transduction is accumulating. In the present study, the activity of the enzyme was investigated in heart tissue under basal conditions and after addition of phorbol esters or aluminum fluoride (AlF inf4 sup− ; 10 mM NaF plus 10 μM AlCl3). Atria of rats and chickens were incubated with [3H]-myristic acid in order to label preferentially phosphatidylcholine. Under basal conditions, the tissues generated choline and phosphatidic acid (PtdOH), the primary catalytic products of phospholipase D. When 0.5 or 2.0% ethanol was present, [3H]-phosphatidyl-ethanol (PETH) was rapidly formed at the expense of [3H]-PtdOH. This transphosphatidylation…

MaleG proteinPhospholipaseBiologyCholineFluorideschemistry.chemical_compoundGTP-Binding ProteinsPhosphatidylcholinePhorbol EstersPhospholipase DAnimalsPhospholipase D activityRats WistarAluminum CompoundsProtein kinase AChromatography High Pressure LiquidProtein Kinase CProtein kinase CPharmacologyEthanolPhospholipase DMyocardiumHeartGeneral MedicinePhosphatidic acidMolecular biologyRatsBiochemistrychemistryChickensAluminumSignal TransductionNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis

2012

Abstract Background Nonalcoholic fatty liver disease is a chronic metabolic disorder with significant impact on cardiovascular and liver mortality. Aims In this study, we examined the effects of silibinin on liver and myocardium injury in an experimental model of nonalcoholic fatty liver disease. Methods A four-week daily dose of silibinin (20 mg/kg i.p.) was administrated to db/db mice fed a methionine–choline deficient diet. Hepatic and myocardial histology, oxidative stress and inflammatory cytokines were evaluated. Results Silibinin administration decreased HOMA-IR, serum ALT and markedly improved hepatic and myocardial damage. Silibinin reduced isoprostanes, 8-deoxyguanosine and nitrit…

MaleGene ExpressionIsoprostanesmedicine.disease_causeGastroenterologyAntioxidantsMicechemistry.chemical_compoundMethionineNon-alcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseasePhosphorylationGastroenterologyAlanine TransaminaseGlutathioneCholine DeficiencyMitochondrial respiratory chainLiverHeart Inflammation NAFLD Oxidative stress SilibininCytokinesmedicine.symptomSilymarinmedicine.medical_specialtySilibininInflammationStatistics NonparametricProinflammatory cytokineInsulin resistanceInternal medicinemedicineAnimalsNitritesAnalysis of VarianceNitratesHepatologySettore BIO/16 - Anatomia Umanabusiness.industryMyocardiumJNK Mitogen-Activated Protein KinasesGlutathionemedicine.diseaseDietFatty LiverOxidative StressEndocrinologychemistrySilybinInsulin ResistancebusinessOxidative stressDigestive and Liver Disease
researchProduct